Table 3. Frequency of HFE genotype and alleles based on sex in TCGA lung cancer (Caucasian patients).
| TCGA LUAD | TCGA LUSC | |||||||
|---|---|---|---|---|---|---|---|---|
| NB (n = 307) | TP (n = 381) | NB (n = 203) | TP (n = 300) | |||||
| Male (n = 140) | Female (n = 167) | Male (n = 172) | Female (n = 209) | Male (n = 151) | Female (n = 52) | Male (n = 219) | Female (n = 81) | |
| Genotype | ||||||||
| H63/D63 (heterozygote) | 37 (26.4%) | 46 (27.5%) | 41 (23.8%) | 57 (27.3%) | 32 (21.2%) | 13 (25.0%) | 46 (21.0%) | 20 (24.7%) |
| D63/D63 (homozygote) | 6 (4.3%) |
7 (4.2%) |
6 (3.5%) |
8 (3.8%) |
3 (2.0%) |
1 (1.9%) |
7 (3.2%) |
3 (3.7%) |
| C282/Y282 (heterozygote) | 12 (8.6%) |
22 (13.2%) | 14 (8.1%) | 30 (14.4%) | 20 (13.2%) | 5 (9.6%) |
27 (12.3%) | 5 (6.2%) |
| Y282/Y282 (homozygote) | 0 (0.0%) | 3 (1.8%) | 1 (0.6%) | 2 (1.0%) | 0 (0.0%) | 1 (1.9%) | 0 (0.0%) | 1 (1.2%) |
| Alleles | ||||||||
| H63D HFE | 49/280 (17.5%) | 60/334 (18.0%) | 53/344 (15.4%) | 73/418 (17.5%) | 38/302 (12.6%) | 15/104 (14.4%) | 60/438 (13.7%) | 26/162 (16.1%) |
| C282Y HFE | 12/280 (4.3%) | 28/334 (8.4%) | 16/344 (4.7%) | 34/418 (8.1%) | 20/302 (6.6%) | 7/104 (6.7%) | 27/438 (6.2%) | 7/162 (4.3%) |
| Fisher’s exact test (Male vs. Female) | p = 0.9142 (H63D) p = 0.0474 (C282Y) |
p = 0.4268 (H63D) p = 0.0549 (C282Y) |
p = 0.6082 (H63D) p = 1.0 (C282Y) |
p = 0.4249 (H63D) p = 0.4308 (C282Y) |
||||
Values were expressed as n = N (%)
LUAD (lung adenocarcinoma)
LUSC (lung squamous cell carcinoma)
NB (blood normal)
TP (tumor patient)